In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase

Cancer Research

Volumn 64, Issue 1, 2004, Pages 1-6

  Shao, Jimin ^b   Zhou, Bingsen ^a   Zhu, Lijun ^b   Qiu, Weihua ^a   Yuan, Yate Ching ^a   Xi, Bixin ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; CYTIDINE DIPHOSPHATE; DEFEROXAMINE MESYLATE; HEPTAPEPTIDE; HYDROXYUREA; IRON; IRON CHELATING AGENT; OXIDOREDUCTASE INHIBITOR; PEPTIDE; PROTEIN HRRM1; PROTEIN HRRM2; PROTEIN P53; PROTEIN P53R2; RADICAL; RIBONUCLEOTIDE REDUCTASE; SCAVENGER; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BINDING AFFINITY; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; DNA REPAIR; DRUG DESIGN; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBUNIT; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROKARYOTE; REDUCTION;

ANTINEOPLASTIC AGENTS; CLONING, MOLECULAR; DNA PRIMERS; DRUG DESIGN; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; HUMANS; KINETICS; MODELS, MOLECULAR; POLYMERASE CHAIN REACTION; PROTEIN CONFORMATION; PROTEIN SUBUNITS; RIBONUCLEOTIDE REDUCTASES;

EID: 1642453838     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3048     Document Type: Article

References (26)

1. Jordan, A., and Reichard, P. Ribonucleotide reductases. Annu. Rev. Biochem., 67: 71-98, 1998.
2. Kauppi, B., Nielsen, B. B., Ramaswamy, S., Larsen, I. K., Thelander, M., Thelander, L., and Eklund, H. The three-dimensional structure of mammalian ribonucleotide reductase protein R2 reveals a more-accessible iron-radical site than Escherichia coli R2. J. Mol. Biol., 262: 706-720, 1996.
3. Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., and Nakamura, Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature (Lond.), 404: 42-49, 2000.
4. Nakano, K., Balint, E., Ashcroft, M., and Vousden, K. H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene, 19: 4283-4289, 2000.
5. 370 of the mouse ribonucleotide reductase R2 protein is the connecting link in the intersubunit radical transfer pathway. J. Biol. Chem., 274: 23746-23751, 1999.
6. Adrait, A., Ohrstrom, M., Barra, A. L., Thelander, L., and Graslund, A. EPR studies on a stable sulfinyl radical observed in the iron-oxygen-reconstituted Y177F/1263C protein R2 double mutant of ribonucleotide reductase from mouse. Biochemistry, 41: 6510-6516, 2002.
7. Eklund, H., Uhlin, U., Farnegardh, M., Logan, D. T., and Nordlund, P. Structure and function of the radical enzyme ribonucleotide reductase. Prog. Biophys. Mol. Biol., 77: 177-268, 2001.
8. Chabes, A., Pfleger, C. M., Kirschner, M. W., and Thelander, L. Mouse ribonucleotide reductase R2 protein: a new target for anaphase-promoting complex-Cdh1-mediated proteolysis. Proc. Natl. Acad. Sci. USA, 100: 3925-3929, 2003.
9. Guittet, O., Hakansson, P., Voevodskaya, N., Fridd, S., Graslund, A., Arakawa, H., Nakamura, Y., and Thelander, L. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J. Biol. Chem., 276: 40647-40651, 2001.
10. Yamaguchi, T., Matsuda, K., Sagiya, Y., Iwadate, M., Fujino, M. A., Nakamura, Y., and Arakawa, H. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res., 61: 8256-8262, 2001.
11. Lozano, G., and Elledge, S. J. p53 sends nucleotides to repair DNA. Nature (Lond.), 404: 24-25, 2000.
12. Zhou, B., Liu, X., Mo. X., Xue. L., Darwish, D., Qiu, W., Shih, J., Hwu, E. B., Luh, F., and Yen, Y. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res., 63: 6583-6594, 2003.
13. Xue, L., Zhou, B., Liu, X., Qiu, W., Jin, Z., and Yen, Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res., 63: 980-986, 2003.
14. Fan, H., Villegas, C., Huang, A., and Wright, J. A. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res., 58: 1650-1653, 1998.
15. Zhou, B. S., Tsai, P., Ker, R., Tsai, J., Ho, R., Yu, J., Shih, J., and Yen, Y. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin. Exp. Metastasis, 16: 43-49, 1998.
16. Kimura, T., Takeda, S., Sagiya, Y., Gotoh, M., Nakamura, Y., and Arakawa, H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat. Genet., 34: 440-4445, 2003.
17. Yen, Y., Grill, S. P., Dutschman, G. E., Chang, C. N., Zhou, B. S., and Cheng, Y. C. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res., 54: 3686-3691, 1994.
18. Richardson, D. R. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol. Hematol., 42: 267-281, 2002.
19. Goan, Y. G., Zhou, B., Hu, E., Mi, S., and Yen, Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res., 59: 4204-4207, 1999.
20. Cooperman, B. S. Oligopeptide inhibition of class I ribonucleotide reductases. Biopolymers, 71: 117-131, 2003.
21. Mann, G. J., Graslund, A., Ochiai, E., Ingemarson, R., and Thelander, L. Purification and characterization of recombinant mouse and herpes simplex virus ribonucleotide reductase R2 subunit. Biochemistry, 30: 1939-1947, 1991.
22. Nyholm, S., Mann, G. J., Johansson, A. G., Bergeron, R. J., Graslund, A., and Thelander, L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem., 268: 26200-26205, 1993.
23. Zhou, B. S., Hsu, N. Y., Pan, B. C., Doroshow, J. H., and Yen, Y. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res., 55: 1328-1333, 1995.
24. Finch, R. A., Liu, M. C., Cory, A. H., Cory, J. G., and Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul., 39: 3-12, 1999.
25. Chaston, T. B., Lovejoy, D. B., Watts, R. N., and Richardson, D. R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res., 9: 402-414, 2003.
26. Ren, S., Wang, R., Komatsu, K., Bonaz-Krause, P., Zyrianov, Y., McKenna. C. E., Csipke, C., Tokes, Z. A., and Lien, E. J. Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents. J. Med. Chem., 45: 410-419, 2002.